As to the development in import volume and corresponding market share, imports originating in Korea hake significantly increased as shown in the table.

(b) a table showing the differences between the expenditure declared under (a) and that declared for the purpose of the interim payments referred to in Article 3(3) of this Regulation;

a table showing the percentage of the employees represented in the sample(s)/register(s) based on the number of employees according to ESA95;

The applications for financing referred to in Article 10 (1) of Regulation (EEC) No 3140/82 must be submitted in the form of the tables shown in the Annexes.

During the investigation period, other imports into the Community originated in several countries including Japan and Singapore as shown in the table below.

(c) a table, extracted from the debtors' ledger, showing the total debts identified but not yet recovered at the end of the financial year for rural development measures.

- revision history: a table showing the revisions in the published year- on- year growth rates for total labour costs using the unadjusted series, for the last 12 quarters;

Tables A. I. 1 and A. I. 2, to show the consequences of allocation of Fisim on figures presented in Chapter 8, 'Sequence of accounts and balancing items' (numerical example).

a table showing the total by allocation of commitments, assigned funds and payments effected during the financial year and aggregate totals since the opening of the EDF;

- a table showing the delays in days in transmitting the data for the last 12 quarters covered by the report and the correspondence between planned and actual date of transmission;

(5) It is necessary to define acceptable methods for determining the underwater weight of potatoes and to provide a table showing the corresponding starch content and aid payable.

The table below shows the growth of the sales volume of the Community industry low range segment compared to an estimate of sales in the same segment by the exporting producers in the countries concerned.

The table below, based on information received by certain companies and contained in the complaint, shows the evolution of sales volume and market share of the other Community producers.

Regulation (EC) No 2516/2000 ensures comparability and transparency among the Member States in the recording of taxes and social contributions in ESA 95 for the excessive deficit procedure.

The results of pharmacology, pharmaco-kinetics and toxicology studies carried out in animals/in vitro shall be provided as factual written and tabulated summaries which shall be presented in the following order:

tables showing by appropriation, country, territory, region or sub-region, the total commitments, assigned funds and payments effected during the financial year and aggregate totals since the opening of the EDF.

The difference between the basic duties so defined and the duties applicable on 1 July 1977, which are shown in the tables annexed to this Protocol, shall be progressively abolished by five reductions of 20 % each to be made on the following dates:

- a graph and a table showing annual unadjusted growth rates of the total labour cost index (NACE Rev. 1 sections) and of the ESA 95 compensation of employees per hours worked (A6 breakdown) with explanations for the differences in the growth rates for the last 12 quarters;

Summary table showing quantities marketed and not put up for sale (tonnes) by recognised producer organisation and by product (listed in Annex II to Regulation (EC) No 2200/96 and, where applicable, not listed in Annex II).

The table below shows the actual development/expected development in consumption from 1995 to 2005. The table also shows that the euro-effect provides a temporary boost to sales over the period 1997 to 2000 and that from 2000 to 2002 consumption is forecast to be lower.

Those reports shall provide cross-references to tabular formats or to the information contained in the main documentation presented in Module 3 (chemical, pharmaceutical and biological documentation), Module 4 (non-clinical documentation) and Module 5 (clinical documentation).

Identify the measures to which additional financing will be granted in the form of State aid (Article 52 of Council Regulation (EC) No 1257/1999). The amount of additional support to be granted for each of the measures concerned during each year covered by the plan should be shown in an indicative table.

In addition to the general transparency requirement for the accounts of operators referred to in point 4.2 as discussed in point 8(b)(vi), Member States must therefore ensure that financial relations between them and those operators are transparent as required by the Directive, so that the following are clearly shown:

(7) The update of the CPV codes and structure should be reflected in the illustrative tables showing the correspondence between the CPV and the Provisional Central Product Classification (CPC Prov.) of the United Nations, the General Industrial Classification of Economic Activities within the European Communities (NACE Rev. 1) and the Combined Nomenclature (CN).

Based on the methodology explained in recitals 136 to 139 of the provisional Regulation, and taking into account the modifications mentioned above and the correction of clerical errors, the difference between the prices, expressed as a percentage of the Community industry's weighted average price (ex works), i.e. the price undercutting margin, is shown in the table below.

an indication of the planned use and form of the financial contribution from the Funds and, where appropriate, the EIB and the other financial instruments including, for information, the total amount from the EAGGF Guarantee Section for the measures referred to in Article 33 of Regulation (EC) No 1257/1999; the expected requirement for technical assistance; an indication as regards additionality in accordance with Article 11(2), whereby for Objective 1 this should take the form of an indicative overall financing table summarising the public or equivalent and, where appropriate, estimated private resources and the Community structural resources allocated corresponding to each priority proposed in the plan.

This is seen in the following table:

Results are provided in Table 6.

A summary of results is presented in Table 3. Table 3

The combined results of these two trials are presented below:

Toxicology Tabulated Summary.

Pharmacology Tabulated Summary

Results from week 54 are shown in Table 4.

Tabulated summary of adverse reactions

Pharmaco-kinetics Tabulated Summary

Tables shall also be drawn up to show the modifications by branch.

The treatment regimen is summarized in Table 4.

Data at one year from BM 16549 are represented in Table 1 and cumulative data for the two years from BM 16549 are represented in table 2.

The in vitro sensitivity to cidofovir is shown in the following table:

The table used for this description shall, proceeding by sector or by branch, show:

Please refer to the table below for the dosing recommendations in adults.

The table shall show, as far as possible and according to national practice:

Reference Nos 26 and 27 are inserted as shown in the following table:

A summary of the key study results from the combined analysis is shown in Table 1.

A summary of the key study results is shown in Table 2.

Efficacy results for studies ACTG 364 and 020 are found in Table 5.

In Cycles 5-9, VELCADE is administered once weekly

Detailed information on dosage recommendations is provided in the following table:

The table used for this description shall show at the level of aggregation used for the calculations:

64 Detailed information on dosage recommendations is provided in the following table: